Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen

“This second DC nomination is a testament to our strong collaboration with Ipsen and once again underscores the dedication and ingenuity of Marengo’s research team in advancing innovative immunotherapy candidates to clinical trials,” said Andrew Bayliffe Ph.D., Chief Scientific Officer of Marengo. “Our novel, first in class TCRVβ-targeted dual T cell agonists drive the revitalization of anti-tumor T cell responses in immunotherapy refractory tumor models, and we look forward to working with Ipsen as we translate this potential into people living with cancer.”

Share:

More News

CEO Snehal Patel commented, “We are very encouraged to see that the preliminary results from FLAMINGO-01 show immune responses in both HLA-A*02 and non-HLA-A*02 patients. We are now considering the merits of adding a randomized placebo arm for non-HLA-A*02 patients, transforming this current open label third arm into effectively a

“At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment,” said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. “These new

“We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products,” said Dr. Harren Jhoti, co-founder, president and chief executive officer of Astex. “Both drug targets are well-characterised drivers of many cancers, and we are excited to be

“We do not view today’s unsatisfactory outcome as a failure of Globo H,” Dr. Heidi Wang, CEO of OBI Pharma added. “There may come a time, with a deeper scientific understanding of the Globo H function, it may play a meaningful role once again.”